Discover the power of real-time signals plus AI
Every contract, funding round, exec hire, and M&A move on Alveo Technologies — with verified, ICP-scored contact reveals (email + mobile) on demand.
Trusted by founders, sales teams, recruiters, and investors at firms like BlackRock, Oracle, Kleiner Perkins, and HubSpot.
Alveo Technologies Receives Agreement from CDC to Develop Point of Need Test for Avian Influenza A(H5) Virus
Contract Type
agreement
AlamedaBiotechnologyHealth CareDescription
Alveo Technologies, Inc. has entered into an agreement with the United States Centers for Disease Control and Prevention (CDC) to develop a rapid, molecular, point of need diagnostic to detect and differentiate between Influenza A + B, and A/H5 in humans. The purpose of this agreement is to support public health preparedness by leveraging Alveo's point of need molecular testing platform for early detection of H5 and seasonal influenza viruses.
Related People
Sign in to view contact details
Sign in to view contact details